Secondary and unspecified malignant neoplasm of lymph nodes
Chapter 2:Neoplasms
ICD-10 C77 is a billable code used to indicate a diagnosis of secondary and unspecified malignant neoplasm of lymph nodes.
C77 refers to secondary malignant neoplasms of lymph nodes, which occur when cancer cells spread from a primary tumor to the lymphatic system. This code encompasses metastatic disease where the origin of the primary tumor is unknown or unspecified. The lymphatic system plays a crucial role in the body's immune response, and when malignant cells infiltrate lymph nodes, it can indicate advanced disease. Patients may present with swollen lymph nodes, systemic symptoms like fever or weight loss, and may require imaging studies for diagnosis. Staging of metastatic lymph node involvement is critical for treatment planning and prognosis. Palliative care considerations are paramount, as many patients with C77 may have advanced cancer requiring symptom management and supportive care rather than curative treatment. Accurate coding is essential for appropriate reimbursement and care management.
Detailed history of the primary cancer, staging information, and treatment plans.
Patients with known primary cancers presenting with lymphadenopathy.
Ensure clear documentation of metastatic disease and any palliative care measures.
Focus on symptom management, patient goals, and quality of life considerations.
Patients with advanced cancer requiring symptom relief and support.
Documentation should reflect the patient's wishes and treatment preferences.
Used when lymph node involvement is suspected and requires histological confirmation.
Document the reason for biopsy and findings.
Oncology specialists should ensure clear documentation of the biopsy results.
Coding C77 accurately reflects the presence of metastatic disease in lymph nodes, which is crucial for treatment planning and prognosis. It also impacts reimbursement and quality of care metrics.
